tetracyclin
develop
result
screen
soil
sampl
antibiot
first
compound
chlortetracyclin
introduc
tetracyclin
found
highli
effect
variou
pathogen
includ
rickettsia
well
gramposit
gramneg
bacteria
thu
becom
first
class
broadspectrum
antibiot
mani
interest
properti
unrel
antibiot
activ
identifi
tetracyclin
led
wide
diverg
experiment
clinic
use
exampl
tetracyclin
also
effect
antimalari
drug
minocyclin
readili
cross
cell
membran
known
potent
antiapoptot
agent
anoth
tetracyclin
doxycyclin
known
exert
antiproteas
activ
doxycyclin
inhibit
matrix
metalloproteinas
contribut
tissu
destruct
activ
diseas
periodont
larg
bodi
literatur
provid
addit
evid
benefici
action
tetracyclin
includ
abil
act
reactiv
oxygen
speci
scaveng
antiinflammatori
agent
review
provid
summari
tetracyclin
multipl
mechan
action
mean
understand
benefici
effect
parent
compound
chlortetracyclin
first
isol
soon
natur
tetracyclin
isol
includ
tetracyclin
tc
famili
molecul
name
two
common
semisynthet
tetracyclin
use
clinic
antibiot
doxycyclin
dox
minocyclin
min
due
broadspectrum
antibiot
efficaci
dox
indic
treatment
varieti
infect
includ
anthrax
chlamydi
infect
communityacquir
pneumonia
lyme
diseas
cholera
syphili
yersinia
pesti
plagu
periodont
infect
other
min
also
display
broadspectrum
efficaci
often
use
clinic
treatment
sever
acn
also
indic
mani
infect
dox
tetracyclin
exert
antibiot
effect
primarili
bind
bacteri
ribosom
halt
protein
synthesi
bacteri
ribosom
highaffin
bind
site
locat
subunit
well
multipl
lowaffin
site
subunit
upon
bind
ribosom
tetracyclin
alloster
inhibit
bind
amino
acyltrna
acceptor
site
asit
protein
synthesi
ceas
use
tetracyclin
declin
recent
decad
due
emerg
resist
strain
bacteria
fig
tetracyclin
also
effect
slowact
antimalari
drug
dox
impair
express
apicoplast
gene
apicoplast
nonphotosynthet
major
organel
found
cell
plant
abnorm
progeni
doxtreat
parasit
tc
dox
min
compos
four
ring
core
attach
variou
side
group
fig
dimethylamino
group
carbon
upper
half
molecul
shown
necessari
antimicrobi
activ
tetracyclin
also
call
chemic
modifi
tetracyclin
cmt
lack
antimicrobi
activ
vivo
presum
due
inabl
molecul
adapt
zwitterion
form
necessari
activ
howev
cmt
retain
abil
bind
nonmicrobi
target
matrix
metalloproteinas
mmp
facilit
use
treatment
diseas
lower
half
molecul
critic
bind
prokaryot
eukaryot
target
interfer
region
reduc
elimin
effect
drug
region
relev
site
metal
ion
chelat
bind
tetracyclin
protein
includ
tetr
may
greatli
enhanc
tetracyclin
complex
dival
metal
ion
ca
mg
bind
tetracyclin
mmp
thought
mediat
chelat
structur
catalyt
zn
ion
within
enzym
fig
addit
bind
bacteri
ribosom
involv
bind
rnabound
mg
strength
tetracyclinemet
interact
depend
tetracyclin
metal
ion
present
gener
affin
tetracyclin
differ
dival
metal
order
decreas
affin
cu
co
fe
zn
mn
mg
ca
affin
also
differ
highli
depend
ph
presenc
metal
ion
rel
superior
dox
mmp
inhibitor
due
increas
affin
zn
compar
tc
min
factor
also
alter
tetracyclin
activ
gener
direct
relationship
lipophil
activ
gramposit
bacteria
lipophil
tc
dox
min
determin
partit
octanol
aqueou
buffer
respect
minimum
inhibitori
concentr
staphylococcu
aureu
gml
respect
lipophil
also
affect
tissu
distribut
min
abl
cross
bloodbrain
barrier
much
readili
dox
tc
min
attain
level
brain
nearli
higher
dox
tc
undetect
brain
probabl
best
character
nonantimicrobi
properti
tetracyclin
abil
inhibit
member
mmp
famili
endopeptidas
mmp
subdivid
base
crude
substrat
specif
collagenas
gelatinas
stromelysin
membranetyp
mmp
mtmmp
collagenas
group
includ
cleav
fibrillar
collagen
type
iii
collagen
fragment
subsequ
denatur
gelatin
gelatinas
includ
proteolyz
gelatin
gelatinas
also
degrad
basement
membran
collagen
type
iv
stromelysin
includ
capabl
degrad
proteoglycan
laminin
fibronectin
collagen
iv
other
cell
membran
anchor
mtmmp
includ
six
differ
mmp
best
character
inhibit
mmp
benefici
mani
patholog
condit
mmpmediat
proteolysi
extracellular
matrix
ecm
contribut
pathogenesi
heart
remodel
tumor
invas
inflamm
current
clinic
avail
mmp
inhibitor
dox
indic
treatment
periodont
mechan
tetracyclin
inhibit
mmp
complet
elucid
believ
exert
antiproteolyt
effect
direct
inhibit
mmp
inhibit
express
direct
inhibit
mmp
appear
mediat
interact
tetracyclin
molecul
metal
ion
within
mmp
appear
mechan
inhibit
depend
chelat
structur
metal
rather
chelat
activ
site
zn
effect
tetracyclin
inhibit
variou
mmp
depend
tetracyclin
speci
mmp
speci
ph
shown
dox
potent
min
tc
collagenas
purifi
rabbit
cornea
ic
valu
respect
trend
may
explain
rel
high
affin
dox
low
affin
tc
zn
ic
valu
dox
collagenas
respect
reason
differ
clear
ph
system
also
affect
inhibit
evidenc
abil
dox
inhibit
ph
inabl
inhibit
ph
addit
inhibit
mmp
directli
tetracyclin
also
inhibit
mmp
synthesi
dox
inhibit
cytokin
induc
mrna
protein
accumul
cultur
rat
synovi
fibroblast
cultur
human
skin
fibroblast
tc
inhibit
induc
express
sinc
mmp
transcript
induc
host
proinflammatori
cytokin
growth
factor
includ
tumor
necrosi
factoralpha
epiderm
growth
factor
other
like
upstream
signal
cascad
lead
mmp
express
import
target
tetracyclin
interest
consequ
mmp
inhibit
indirect
inhibit
serin
proteas
mmp
inactiv
serin
proteas
inhibitor
serpin
mmp
inhibit
dox
cmt
preserv
serpin
therebi
block
serin
proteas
activ
anoth
wellcharacter
nonantimicrobi
properti
tetracyclin
abil
scaveng
reactiv
oxygen
speci
ro
dox
min
tc
multiplesubstitut
phenol
ring
similar
vitamin
e
phenol
ring
key
rosscaveng
abil
compound
reaction
phenol
ring
free
radic
gener
phenol
radic
becom
rel
stabl
unreact
due
reson
stabil
steric
hindranc
phenol
ring
side
group
min
directli
scaveng
ro
sever
cellfre
mixedrad
assay
potenc
compar
vitamin
e
depend
assay
use
min
ic
time
potent
scaveng
dox
time
potent
tc
superior
scaveng
abil
min
like
due
presenc
diethyamino
group
phenol
carbon
fig
tetracyclin
possess
antiapoptot
properti
fig
min
dox
increas
surviv
hippocamp
neuron
follow
global
brain
ischemia
gerbil
protect
associ
reduc
express
min
evalu
sever
model
neuron
injuri
found
also
protect
huntington
diseas
traumat
brain
injuri
parkinson
diseas
key
event
execut
apoptot
cascad
activ
caspas
famili
cystein
proteas
neuroprotect
min
associ
reduct
andor
express
suggest
min
protect
inhibit
express
key
factor
within
apoptot
cascad
addit
inhibit
caspas
express
min
also
shown
inhibit
caspas
activ
block
activ
zhu
et
al
demonstr
min
inhibit
cytochrom
c
releas
activ
mice
amyotroph
later
sclerosi
use
isol
mitochondria
also
show
min
inhibit
mitochondri
swell
induc
ca
bid
proapoptop
cytoclasm
factor
well
cytochrom
c
releas
indic
mitochondria
perhap
mptp
mitochondri
permeabl
transit
pore
direct
target
min
benefici
effect
tc
like
associ
aggreg
benefici
action
includ
inhibit
proinflamma
tori
cytokin
level
mmp
ro
dox
success
use
treatment
skin
condit
acn
rosacea
biopsi
inflammatori
lesion
patient
acn
yield
increas
proinflammatori
cytokin
cytokin
known
induc
increas
mmp
level
activ
ro
also
describ
play
role
pathophysiolog
rosacea
like
mediat
increas
vessel
permeabl
edema
may
support
erythema
develop
action
add
antiinflammatori
profil
ttc
min
lesser
extent
dox
inhibit
phospolipas
inhibit
neutrophil
migrat
adher
prolifer
lymphocyt
featur
aggreg
antiinflammatori
profil
tc
tetracyclin
report
concentr
site
tissu
injuri
investig
use
radiolabel
tc
note
capac
accumul
damag
myocardium
use
diagnos
infarct
result
demonstr
correl
infarct
size
determin
radiolabel
tc
serum
creatin
kinas
abil
tc
concentr
tissu
well
known
dentist
take
advantag
high
concentr
dox
periostat
inflammatori
exud
periodont
lesion
gingiv
crevicular
fluid
mean
treat
periodont
gingiv
fibroblast
transport
min
concentr
temperaturedepend
manner
steadi
state
cellularextracellular
concentr
ratio
min
uptak
tetracyclin
also
observ
neutrophil
may
partli
explain
high
level
observ
injur
tissu
romeroperez
et
al
explor
capac
min
accumul
myocardi
tissu
cell
min
accumul
myocardium
severalfold
greater
plasma
level
accumul
pronounc
ischem
normal
myocardium
cardiac
fibroblast
myocyt
possess
compar
uptak
system
report
gingiv
cell
intracellular
concentr
could
theori
reach
millimolar
level
concentr
mass
action
effect
like
seen
drug
may
time
exert
potent
antioxid
antimmp
effect
balanc
ultim
translat
cytoprotect
effect
class
drug
report
exert
uniqu
effect
complex
patholog
experiment
simian
immunodefici
viru
siv
model
hiv
central
nervou
system
cn
diseas
min
reduc
sever
enceph
suppress
viral
load
brain
decreas
express
cn
inflammatori
marker
tetracyclin
also
demonstr
protect
effect
prion
prp
sc
mediat
brain
damag
anim
inject
intracerebr
scrapieinfect
brain
show
signific
delay
onset
clinic
sign
diseas
prolong
surviv
time
mm
tc
inocul
tc
preincub
highli
dilut
scrapieinfect
inoculum
onethird
treat
hamster
develop
diseas
thu
tetracyclin
appear
reduc
prion
infect
direct
interact
prp
sc
potenti
use
inactiv
bseor
vcjdcontamin
product
prevent
strategi
agent
acut
damag
tissu
live
organ
mustard
ga
alkyl
agent
caus
massiv
blister
skin
sever
damag
lung
activ
proteas
includ
elastas
mmp
amongst
effect
studi
guignabert
et
al
guinea
pig
given
mustard
ga
intratrach
group
anim
pretreat
dox
result
decreas
gelatinas
activ
decreas
inflamm
notabl
decreas
histolog
lung
epitheli
lesion
acut
respiratori
distress
syndrom
ard
develop
set
diseas
sepsi
ard
infiltr
lung
neutrophil
lead
massiv
activ
cell
yield
local
tissu
destruct
possibl
death
subject
destruct
lung
tissu
document
bronchial
lavag
presenc
proteas
elastas
mmp
collagen
elastin
fragment
emerg
new
epidem
ard
may
import
caus
sever
diseas
death
augment
spectrum
possibl
use
tetracyclin
prevent
limit
develop
respiratori
system
complic
case
influenza
sar
sever
acut
respiratori
distress
syndrom
caus
coronaviru
potenti
scenario
may
high
risk
exposur
contamin
mutat
version
viru
case
influenza
medic
personnel
use
tetracyclin
may
justifi
mean
prevent
seriou
complic
develop
upon
exposur
infect
cmt
particular
also
examin
anticanc
therapeut
potenti
mmp
involv
tumor
metastasi
angiogenesi
overexpress
kaposi
sarcoma
ks
cell
administ
mgday
demonstr
antitumor
activ
similar
promis
investig
ks
drug
tetracyclin
recogn
slowli
time
genr
drug
interest
pleiotrop
properti
accumul
injur
tissu
make
almost
appear
act
smart
drug
recognit
scientist
clinician
collect
properti
safeti
profil
class
drug
led
implement
clinic
trial
explor
possibl
benefici
effect
set
wide
varieti
diseas
cmt
proven
gener
use
deriv
uniqu
properti
ration
modif
class
drug
may
lead
develop
novel
compound
greater
therapeut
potenti
safeti
profil
inde
creativ
effort
current
focu
variou
research
group
add
ref
howev
recogn
member
ttc
famili
similar
importantli
distinct
properti
halflif
lipophil
scientist
anticip
use
need
make
extens
consider
toward
desir
prefer
action
eg
antiapoptot
vs
antiproteas
anticip
outcom
